DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for sex cord-stromal tumor — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSex cord-stromal tumor maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for sex cord-stromal tumor is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
GNAS complex locus (GNAS) — GNAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet oladrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8WW2 · 2.79 Å · ligand OLEIC ACID (OLA). Experimental structure, not a prediction.
What the evidence adds up to
Ovarian sex cord-stromal tumours are rare, accounting for about 7% of all primary ovarian tumours. They arise from stromal cells and primitive sex cords, and common types include granulosa cell tumours, fibrothecomas, sclerosing stromal tumours, and Sertoli-Leydig cell tumours. Most present as low-grade disease in younger patients and are often unilateral. Because the tumour cells produce steroid hormones, patients can show hyperandrogenic virilising states or hyperestrogenic manifestations. The World Health Organization classification has been revised, regrouping these tumours into pure stromal, pure sex cord, and mixed sex cord-stromal tumours; entities such as stromal luteoma and gynandroblastoma are no longer considered separate. The most useful immunohistochemical marker for identification is alpha-inhibin, which is positive in most neoplasms in this group.
Treatment is primarily surgical, and the prognosis is generally good. For paediatric and adolescent patients, staging for ovarian sex cord-stromal tumours follows the International Federation of Gynecology and Obstetrics classification for ovarian carcinoma. Virtually all testicular sex cord-stromal tumours in children present as localised, nonmetastatic tumours with excellent prognosis after complete resection. The prognosis of ovarian sex cord-stromal tumours can be adversely affected by tumour spillage during surgery or by the presence of metastases. In those high-risk cases, cisplatin-based chemotherapy is recommended. Some sex cord-stromal tumours develop in the context of tumour predisposition syndromes such as DICER-1, so specific follow-up is indicated.
The 2021 consensus recommendations from the EXPeRT/PARTNER groups state that sex cord-stromal tumours should be diagnosed and treated according to standardised recommendations that include reference pathology, genetic testing for tumour predisposition syndromes in selected cases, and stratified adjuvant chemotherapy in patients with an unfavourable risk profile. The authors recommend that patients be enrolled into prospective registries to ensure high quality of diagnosis and therapy. A 2006 review notes that future classifications should incorporate new knowledge from more sophisticated clinicopathologic studies and advanced molecular techniques.
What is still missing are prospective registry data large enough to define optimal treatment strategies for these rare tumours, particularly for children and adolescents. The molecular underpinnings are still being integrated with morphologic and immunohistochemical findings to refine diagnostic and prognostic stratification. No randomised trial data exist to compare chemotherapy regimens or to determine whether any drug can be repurposed for this disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Roentgenology · 2005 · 167 citations
CT and MRI Findings of Sex Cord–Stromal Tumor of the Ovary
AbstractOBJECTIVE: The purpose of this article was to research the clinical and imaging features of sex cord-stromal tumors of the ovary to help in specific diagnosis of ovarian tumors. Sex cord-stromal tumors of the ovary are rare ovarian neoplasms, which arise from stromal cells and primitive sex cords in the ovary. The common types are granulosa cell tumors, fibrothecomas, sclerosing stromal tumors, and Sertoli-Leydig cell tumors. They account for most of the hormonally active ovarian tumors. They have characteristic imaging features in each type of the tumor. CONCLUSION: Clinical and radiologic clues are helpful in differential diagnosis from the more common epithelial tumors; sex cord-stromal tumors primarily are treated surgically and have generally good prognosis.
Diagnostic and Interventional Radiology · 2015 · 152 citations · open access
Sex cord-stromal tumors of the ovary: a comprehensive review and update for radiologists
AbstractOvarian sex cord-stromal tumors are infrequent and represent approximately 7% of all primary ovarian tumors. This histopathologic ovarian tumor group differs considerably from the more prevalent epithelial ovarian tumors. Although sex cord-stromal tumors present in a broad age group, the majority tend to present as a low-grade disease that usually follows a nonaggressive clinical course in younger patients. Furthermore, because the constituent cells of these tumors are engaged in ovarian steroid hormone production (e.g., androgens, estrogens, and corticoids), sex cord-stromal tumors are commonly associated with various hormone-mediated syndromes and exhibit a wide spectrum of clinical features ranging from hyperandrogenic virilizing states to hyperestrogenic manifestations. The World Health Organization sex cord-stromal tumor classification has recently been revised, and currently these tumors have been regrouped into the following clinicopathologic entities: pure stromal tumors, pure sex cord tumors, and mixed sex cord-stromal tumors. Moreover, some entities considered in the former classification (e.g., stromal luteoma, stromal tumor with minor sex cord elements, and gynandroblastoma) are no longer considered separate tumors in the current classification. Herein, we discuss and revise the ultrasonography, computed tomography, and magnetic resonance imaging characteristics of the different histopathologic types and clinicopathologic features of sex cord-stromal tumors to allow radiologists to narrow the differential diagnosis when facing ovarian tumors.
International Journal of Gynecological Pathology · 2006 · 108 citations
Recent Advances in the Pathology and Classification of Ovarian Sex Cord-Stromal Tumors
AbstractIn recent years, our knowledge of ovarian sex cord-stromal tumors has increased, and their classification has evolved. In this review, recent advances in the classification and pathology of ovarian sex cord-stromal tumors are discussed, and the controversy regarding the classification of sex cord tumor with annular tubules is addressed. The current classification is built on those of the past, and future classifications should improve on what is now in place incorporating new knowledge from more sophisticated clinicopathologic studies and advanced molecular techniques. This review emphasizes articles written in the 21st century as well as those that have significantly advanced our knowledge of sex cord-stromal tumors in past decades. The tumors in this group occur over a wide age range and are often unilateral. In difficult cases, immunocytochemistry provides improved diagnostic accuracy. The most useful immunohistochemical marker for their identification is alpha-inhibin, which is positive in most neoplasms in the sex cord-stromal group. The article concludes with a section discussing the pathogenesis of sex cord-stromal tumors.
Journal of Pediatric Hematology/Oncology · 2012 · 54 citations
Management of Ovarian and Testicular Sex Cord-stromal Tumors in Children and Adolescents
AbstractPediatric ovarian and testicular sex cord-stromal tumors are distinct from germ cell neoplasms and may present with palpable mass or signs of hormone production. Both may be associated with specific genetic syndromes. Staging for ovarian sex cord-stromal tumors is based on the International Federation of Gynecology and Obstetrics classification for ovarian carcinoma. Treatment for those with high risk disease includes multiagent chemotherapy. Testicular stromal tumors often, though not always, follow a benign course. Additional research will help to define optimal treatment strategies for children with these rare tumors.
Consensus recommendations from the EXPeRT/PARTNER groups for the diagnosis and therapy of sex cord stromal tumors in children and adolescents
AbstractAs part of the European Union-funded project designated Paediatric Rare Tumours Network - European Registry (PARTNER), the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) is continuously developing consensus recommendations in order to harmonize standard care for very rare solid tumors of children and adolescents. This paper presents the internationally recognized recommendations for the diagnosis and treatment of sex cord stromal tumors (SCST). The clinical approach to sex cord stromal tumors of the testis (TSCST) and ovary (OSCST) depends on histological differentiation and tumor stage. Virtually all TSCSTs present as localized nonmetastatic tumors, with excellent prognosis after complete resection. In contrast, the prognosis of OSCSTs may be adversely affected by tumor spillage during surgery or presence of metastases. In these cases, cisplatin-based chemotherapy is recommended. Of note, some SCSTs may develop in the context of tumor predisposition syndromes, for example, DICER-1, so that specific follow-up is indicated. SCSTs should be diagnosed and treated according to standardized recommendations that include reference pathology, genetic testing for tumor predisposition syndromes in selected cases, and stratified adjuvant chemotherapy in patients with unfavorable risk profile. To ensure high quality of diagnosis and therapy, patients should be enrolled into prospective registries.
National Conference on Artificial Intelligence · 1993 · 10 citations
A method for development of dialogue managers for natural language interfaces
AbstractThis article focuses on the recent advances in ovarian sex cord-stromal tumors, predominantly in the setting of their molecular underpinnings. The integration of genetic information with morphologic and immunohistochemical findings in this rare subset of tumors is of clinical significance from refining the diagnostic and prognostic stratifications to genetic counseling.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
